prednisone has been researched along with bendamustine hydrochloride in 81 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.47) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (6.17) | 29.6817 |
| 2010's | 47 (58.02) | 24.3611 |
| 2020's | 27 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anger, G; Herold, M; Höche, D; Kästner, R | 1 |
| Arnold, W; Henneberger, G; Nowak, C; Tanneberger, S | 1 |
| Niederwieser, D; Pönisch, W | 1 |
| Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C | 1 |
| Assmann, M; Bittrich, A; Dachselt, K; Freund, M; Friedrich, T; Grobe, N; Harksel, B; Helbig, W; Herold, M; Merkle, K; Mitrou, PS; Niederwieser, D; Pasold, R; Pönisch, W; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Stelzer, E; Subert, R; Wilhelm, G | 1 |
| Ogura, M | 1 |
| Cheson, BD | 1 |
| Czuczman, MS; Leonard, JP; Williams, ME | 1 |
| Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N | 1 |
| Alamdari, HS; Cassarino, DS; Chiu, MW; Pinter-Brown, L | 1 |
| Giné, E; Gutiérrez-García, G; López-Guillermo, A | 1 |
| Austein, T; Demme, B | 1 |
| Dietrich, S; Ho, A; Schmitt, T; Walter, E; Witzens-Harig, M | 1 |
| Gaertner, EM; Switlyk, SA | 1 |
| Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Casini, M; Cavattoni, IM; Cortelazzo, S; Deola, S; Farsad, M; Mian, M; Pescosta, N | 1 |
| Dreyling, M; Gafter-Gvili, A; Gurion, R; Raanani, P; Shpilberg, O; Vidal, L | 1 |
| Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T | 1 |
| Ballo, H; Balser, C; Banat, GA; Barth, J; Brugger, W; Dürk, H; Heil, G; Hinke, A; Hoelzer, D; Kaiser, U; Kofahl-Krause, D; Losem, C; Maschmeyer, G; Niederle, N; Roller, F; Rummel, MJ; Stauch, M; von Grünhagen, U; Weidmann, E; Welslau, M | 1 |
| Cheson, BD; Ujjani, C | 1 |
| Carrigan, CN; Chicklas, S; Chittenden, T; Deckert, J; Erickson, HK; Lai, KC; Lambert, JM; Li, M; Lutz, RJ; Mayo, MF; Park, PU; Pinkas, J; Yi, Y | 1 |
| Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L | 1 |
| Castaigne, JG; Dewilde, S; Dunlop, W; Parker, C; Woods, B | 1 |
| Burke, JM; Chen, L; Clementi, R; Craig, M; Flinn, IW; Hallman, DM; Hawkins, TE; Hertzberg, M; Issa, S; Kahl, BS; Kolibaba, K; Kwan, YL; Macdonald, D; Munteanu, M; Simpson, D; van der Jagt, R; Wood, P | 1 |
| Aoki, S | 1 |
| Abenhardt, W; Dörfel, S; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Meyer, D; Münz, M | 1 |
| Baumann, FT; Bloch, W; Elter, T; Fiebig, L; Hahn, M; Hallek, M; Hülsdünker, T; Mierau, A; Reinart, N; Schenk, A; Strüder, HK; Zimmer, P | 1 |
| Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
| Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Izutsu, K | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| AlAli, HK; Andrea, M; Becker, C; Edelmann, T; Franke, GN; Gutsche, K; Hammerschmidt, D; Heyn, S; Hoffmann, FA; Holzvogt, B; Jentzsch, M; Kreibich, U; Lange, T; Leiblein, S; Niederwieser, D; Plötze, M; Poenisch, W; Reifenrath, K; Schliwa, T; Schwarz, M; Schwarzbach, H; Schwarzer, A; Schwind, S; Vucinic, V; Zehrfeld, T | 1 |
| Barth, J; Brugger, W; Bruns, I; Czibere, A; Fenk, R; Germing, U; Haas, R; Heil, G; Kobbe, G; Kofahl-Krause, D; Kronenwett, R; Losem, C; Maschmeyer, G; Niederle, N; Pechtel, S; Rummel, MJ; Schroeder, T; Welslau, M; Zohren, F | 1 |
| Burke, JM; Craig, M; Flinn, IW; Hawkins, TE; Hertzberg, M; Issa, S; Kahl, BS; Kolibaba, K; MacDonald, D; Munteanu, M; Simpson, D; van der Jagt, RH; Victor, TW; Wood, P | 1 |
| Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S | 1 |
| Collar, JM; López-Guillermo, A; Oyagüez, I; Rueda, A; Sabater, E; Salar, A | 1 |
| Cuzzocrea, S; Ferrero, S; Ghione, P; Mauro, E; Mian, M; Mondello, P; Pitini, V; Steiner, N; Visentin, A; Wasle, I; Willenbacher, W; Zaja, F; Zambello, R | 1 |
| Chan, TS; Khong, PL; Kwong, YL | 1 |
| Díaz, MG; Dreyling, M; Dyer, MJ; Grigg, A; Knapp, A; Lei, G; Marlton, P; Rule, S; Wassner-Fritsch, E | 1 |
| Castillo, JJ; Olszewski, AJ; Reagan, JL | 1 |
| Cerchione, C; Cuzzocrea, S; Ferrero, S; Mauro, E; Mian, M; Mondello, P; Nappi, D; Steiner, N; Willenbacher, W | 1 |
| Doorduijn, JK; Kluin-Nelemans, JC | 1 |
| Cheng, CL; Chou, SC; Liu, JH; Tang, JL; Tien, HF; Yao, M | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| Allen, J; Badillo, M; Lee, HJ; Ok, CY; Prabhu, V; Romaguera, JE; Sadimin, ET; Schalop, L; Schenkel, J; Tarapore, R; Wang, M; Zloza, A | 1 |
| Barbui, AM; Burciu, A; Canales, MA; Cannell, PK; Collins, GP; Dürig, J; Fingerle-Rowson, G; Forstpointner, R; Herold, M; Hertzberg, M; Hiddemann, W; Klanova, M; Marcus, RE; Nielsen, T; Radford, J; Seymour, JF; Tobinai, K; Trotman, J; Wolbers, M | 1 |
| Basta, I; Doneddu, PE; Eftimov, F; Gallia, F; Nikolic, A; Nobile-Orazio, E; Peric, S; van Lieverloo, GGA; van Schaik, IN; Verhamme, C; Wieske, L | 1 |
| Alderuccio, JP; Becnel, MR; Caimi, P; Calzada, O; Cerhan, JR; Cohen, JB; Desai, A; Evens, AM; Fakhri, B; Ghosh, N; Goldman, ML; Habermann, TM; Hill, BT; Hussain, MJ; Jagadeesh, D; Kahl, BS; Kodali, A; Link, BK; Lossos, IS; Martin, P; Maurer, MJ; Mehra, P; Mukhija, D; Nastoupil, L; Portell, CA; Reddy, P; Smith, SD; Tiutan, T; Winter, AM | 1 |
| Dawson, K; Guzauskas, GF; Masaquel, A; Thuresson, PO; Veenstra, DL | 1 |
| Burke, JM; Chang, J; Chen, L; Flinn, IW; Hallman, D; Hawkins, T; Issa, S; Kahl, B; Kolibaba, K; MacDonald, D; Simpson, D; Trotman, J; van der Jagt, R; Wood, P | 1 |
| Buchheit, V; Cartron, G; Fingerle-Rowson, G; Frey, N; Gibiansky, E; Gibiansky, L; Hargreaves, CE; Hiddemann, W; Jamois, C; Marcus, R; Meneses-Lorente, G; Sahin, D; Seymour, JF; Strefford, JC | 1 |
| Dreyling, M; Gafter-Gvili, A; Gurion, R; Shargian, L; Vidal, L | 1 |
| Berdeja, JG; Daniel, DB; Erter, J; Flinn, IW; Mace, JR | 1 |
| Butera, JN; Castillo, JJ; Olszewski, AJ; Reagan, JL | 1 |
| Byun, JM; Eom, HS; Jo, JC; Kang, HJ; Kim, HJ; Kim, SJ; Lee, HS; Lee, JO; Lee, SI; Lee, Y; Park, Y; Shin, HJ; Suh, C; Yang, DH; Yhim, HY; Yoo, KH | 1 |
| Dingeldein, G; Goldschmidt, H; Habermehl, C; Knauf, W; Kunz, C; Moehler, T; Raab, MS; Schlag, R; Terzer, T; Walter, S; Welslau, M | 1 |
| Jaksic, O; Lucijanic, M | 1 |
| Böttcher, S; Hauf, E; Herold, M; Hirt, C; Kahl, C; Kämpfe, D; Keller, U; Klapper, W; Koch, K; Kroschinsky, F; La Rosée, P; Marks, R; Maschmeyer, G; Meissner, J; Meyer, A; Monecke, A; Pouyiourou, M; Prange-Krex, G; Schmalenberg, H; Scholz, CW; Stroux, A; Viardot, A; Vucinic, V; Weber, T; Witzens-Harig, M | 1 |
| Cerchione, C; Cimmino, I; De Renzo, A; Lucchesi, A; Martinelli, G; Musuraca, G; Nappi, D; Pane, F | 1 |
| Cabras, MG; Caocci, G; Dessì, D; La Nasa, G; Mantovani, D; Moi, G; Mulas, O | 1 |
| Andrea, M; Becker, C; Bill, M; Braunert, L; Edelmann, T; Franke, GN; Grimm, J; Hammerschmidt, D; Hoffmann, FA; Holzhey, T; Holzvogt, B; Holzvogt, M; Jentzsch, M; Platzbecker, U; Pönisch, W; Remane, Y; Scholz, M; Schönfelder-Fricke, U; Schwarz, M; Schwarzer, A; Schwind, S; Wang, SY; Zehrfeld, T | 1 |
| Abi Hatem, N; Dameron, M; Gupta, N; Horowitz, M | 1 |
| Bolen, CR; Herold, M; Hiddemann, W; Huet, S; Klapper, W; Marcus, R; Mattiello, F; Mir, F; Nielsen, T; Oestergaard, MZ; Salles, G; Venstrom, JM; Weigert, O | 1 |
| Byfield, SD; Kabadi, SM; LE, L; Olufade, T | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Davis, K; Du, XL; Goyal, RK; Jain, P; Kabadi, SM; Kaye, JA; Le, H; Nagar, SP; Wang, M | 1 |
| Allmer, C; Ansell, SM; Castellino, A; Cerhan, JR; Cohen, JB; Farooq, U; Feldman, AL; Habermann, TM; Inwards, DJ; Larson, MC; Link, BK; Martin, P; Maurer, MJ; Nowakowski, GS; Paludo, J; Slager, SL; Syrbu, SI; Wang, Y; Witzig, TE | 1 |
| Leslie, LA | 1 |
| Albertsson-Lindblad, A; Glimelius, I; Jerkeman, M; Palsdottir, T; Smedby, KE; Weibull, CE | 1 |
| Cahill, KE; Smith, SM | 1 |
| Jiang, T; Ou, W; Tang, X | 1 |
| Bosly, A; Dreyling, M; Freeman, CL; Gerrie, AS; Hermine, O; Hoster, E; Klapper, W; Ramsower, CA; Rimsza, LM; Savage, KJ; Scott, DW; Sehn, LH; Szymczyk, M; Unterhalt, M; Villa, D | 1 |
| Edina, BC; Rinaldi, I | 1 |
| Bastos Oreiro, M; Buño, I; Carbonell, D; Chicano, M; Díaz Crespo, FJ; Diez Martín, JL; Kwon, M; Martín Rojas, R; Martínez-Laperche, C; Menárguez, J; Muñiz, P; Sanz-Villanueva, L; Suárez-González, J | 1 |
| Sheng, Z; Wang, L | 1 |
| Ishiwata, K; Kageyama, K; Kaji, D; Mori, YA; Nishida, A; Shimizu, Y; Takagi, S; Taniguchi, S; Taya, Y; Uchida, N; Wake, A; Watanabe, O; Yamaguchi, K; Yamamoto, G; Yamamoto, H | 1 |
| Abeykoon, JP; Kapoor, P; Paludo, J | 1 |
| Ballerini, F; Bari, A; Califano, C; Capponi, M; Catellani, H; Conconi, A; Federico, M; Galimberti, S; Ghiggi, C; Gini, G; Liberati, AM; Luminari, S; Manni, M; Mannina, D; Marcheselli, L; Massaia, M; Merli, M; Musto, P; Musuraca, G; Nizzoli, ME; Pastore, D; Pennese, E; Perrone, T; Pulsoni, A; Re, F; Skrypets, T; Stefani, PM; Usai, SV; Vitolo, U | 1 |
| Aktar, SJ; Ante, Z; Chan, KKW; Cheung, MC; Liu, N; Prica, A; Suleman, A | 1 |
| Caces, DB; Curtis, M; Danielewicz, I; Freeman, J; García-Sancho, AM; Glazunova, V; Grigg, A; Henninger, T; Hess, G; Hou, JZ; Janssens, A; Kim, SJ; Masliak, Z; McKay, P; Merli, F; Munakata, W; Nagai, H; Nastoupil, LJ; Özcan, M; Pavlovsky, MA; Preis, M; Qin, R; Rowe, M; Salles, G; Tamegnon, M; Thieblemont, C; Wang, T | 1 |
18 review(s) available for prednisone and bendamustine hydrochloride
| Article | Year |
|---|---|
[Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Gene Targeting; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Nitrogen Mustard Compounds; Prednisone; Prognosis; Purine Nucleosides; Pyrimidinones; Risk; Rituximab; Salvage Therapy; Sirolimus; Transplantation, Autologous; Vincristine | 2008 |
Current immunochemotherapy strategies in follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Nitrogen Mustard Compounds; Prednisone; Radioimmunotherapy; Rituximab; Stem Cell Transplantation; Vidarabine; Vincristine | 2010 |
Cutaneous granulomatous vasculitis associated with chronic lymphocytic leukemia: case report and review of literature of a rare entity.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bendamustine Hydrochloride; Biopsy; Erythrocyte Transfusion; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Paraneoplastic Syndromes; Prednisone; Skin Diseases, Vascular; Treatment Outcome; Vasculitis | 2012 |
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Prednisone; Recurrence; Vincristine; Waldenstrom Macroglobulinemia | 2012 |
The optimal management of follicular lymphoma: an evolving field.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Induction Chemotherapy; Lymphoma, Follicular; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prednisone; Prognosis; Rituximab; Vincristine | 2013 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine | 2014 |
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
[Management of follicular lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Consolidation Chemotherapy; Cyclophosphamide; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lymphoma, Follicular; Maintenance Chemotherapy; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Predictive Value of Tests; Prednisolone; Prednisone; Prognosis; Rituximab; Vincristine | 2014 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia | 2016 |
What is the optimal initial management of the older MCL patient?
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Prednisone; Rituximab; Survival Rate; Vincristine | 2018 |
Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Maintenance Chemotherapy; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Vincristine | 2019 |
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Receptors, Chimeric Antigen; Risk Assessment; Rituximab; Stem Cell Transplantation; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Follicular Lymphoma: a Focus on Current and Emerging Therapies
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Genetic Testing; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Prednisone; Pyridones; Rituximab; Sulfonamides; Vincristine | 2022 |
BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell; Prednisone; Quality of Life; Rituximab; Vincristine | 2023 |
Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisone; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2022 |
Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Network Meta-Analysis; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2023 |
Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
Topics: Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Humans; Myeloid Differentiation Factor 88; Prednisone; Randomized Controlled Trials as Topic; Retrospective Studies; Rituximab; Vincristine; Waldenstrom Macroglobulinemia | 2023 |
19 trial(s) available for prednisone and bendamustine hydrochloride
| Article | Year |
|---|---|
[Preliminary results of cyclically alternating chemotherapy (CVPP/DBVCy) in advanced Hodgkin's disease].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Clinical Trials as Topic; Daunorubicin; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Lomustine; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Random Allocation; Vinblastine; Vincristine | 1987 |
[Animal experimental examination of a phase III study on the effect of the combination therapy of bruneomycin, cytostasan and prednisone].
Topics: Animals; Bendamustine Hydrochloride; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Male; Mice; Neoplasms, Experimental; Nitrogen Mustard Compounds; Prednisone; Sarcoma, Experimental; Streptonigrin | 1983 |
Bendamustine in the treatment of multiple myeloma: results and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Prospective Studies; Remission Induction; Survival Rate | 2002 |
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Germany, East; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Quality of Life; Remission Induction; Survival Analysis; Time Factors; Treatment Failure | 2006 |
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Prospective Studies; Rituximab; Treatment Outcome; Vincristine | 2013 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Nitrogen Mustard Compounds; Paresthesia; Peripheral Nervous System Diseases; Prednisone; Rituximab; Treatment Outcome; Vincristine; Vomiting | 2014 |
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Oncogene Proteins, Fusion; Prednisone; Prognosis; Rituximab; Vincristine | 2015 |
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Quality of Life; Rituximab; Surveys and Questionnaires; Vincristine | 2016 |
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Progression-Free Survival; Rituximab; Vincristine; Young Adult | 2018 |
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Survival Rate; Vincristine | 2019 |
Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Drug Costs; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Prognosis; Quality-Adjusted Life Years; Rituximab; Survival Rate; United States; Vincristine; Young Adult | 2019 |
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Progression-Free Survival; Proportional Hazards Models; Rituximab; Survival Rate; Vincristine | 2019 |
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Body Weight; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Models, Biological; Prednisone; Progression-Free Survival; Sex Factors; Treatment Outcome; Vincristine | 2019 |
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Rituximab; Standard of Care; Vincristine | 2019 |
First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Progression-Free Survival; Renal Insufficiency; Treatment Outcome | 2020 |
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Ki-67 Antigen; Lactate Dehydrogenases; Lymphoma, Mantle-Cell; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Transplantation, Autologous; Vincristine; Young Adult | 2022 |
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Prednisone; Rituximab; Vincristine | 2023 |
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Piperidines; Prednisone; Rituximab; Vincristine | 2023 |
44 other study(ies) available for prednisone and bendamustine hydrochloride
| Article | Year |
|---|---|
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine | 2008 |
Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Prednisone; Protein Kinase Inhibitors; Rituximab; TOR Serine-Threonine Kinases; Vincristine | 2010 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine | 2010 |
Severe cutaneous interface drug eruption associated with bendamustine.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Drug Eruptions; Humans; Lymphoma, B-Cell; Male; Nitrogen Mustard Compounds; Prednisone; Vincristine | 2010 |
Uncommon recurrence of follicular lymphoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Head and Neck Neoplasms; Humans; Lymphoma, Follicular; Male; Nitrogen Mustard Compounds; Prednisone; Remission Induction; Rituximab; Skin Neoplasms | 2012 |
Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Retrospective Studies; Rituximab; Vincristine | 2012 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2012 |
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Deoxycytidine; Doxorubicin; Etoposide; Fatal Outcome; Female; Gemcitabine; Graft vs Host Disease; Hodgkin Disease; Humans; Ifosfamide; Male; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Procarbazine; Recurrence; Reoperation; Rituximab; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine; Vinorelbine; Young Adult | 2013 |
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Recurrence; Retrospective Studies | 2013 |
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Cell Line, Tumor; Cyclophosphamide; Cytotoxicity, Immunologic; Drug Screening Assays, Antitumor; Female; Humans; Immunotoxins; Maytansine; Mice; Mice, SCID; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Prednisone; Rituximab; Tetraspanins; Vincristine; Xenograft Model Antitumor Assays | 2013 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies | 2013 |
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; England; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rituximab; Vincristine; Wales | 2014 |
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Germany; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Office Visits; Prednisone; Prospective Studies; Registries; Rituximab; Vidarabine | 2015 |
Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab a
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Brain-Derived Neurotrophic Factor; Cognition Disorders; Cyclophosphamide; Doxorubicin; Electroencephalography; Fatigue; Female; Humans; Interleukin-6; Lymphoma, Non-Hodgkin; Male; Middle Aged; Outcome Assessment, Health Care; Prednisone; Rituximab; Surveys and Questionnaires; Vincristine | 2015 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Blood Component Removal; Bortezomib; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Costs and Cost Analysis; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Therapy, Combination; Humans; Lymphoma, Follicular; Markov Chains; Prednisone; Quality-Adjusted Life Years; Rituximab; Spain; Vincristine | 2016 |
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine | 2016 |
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine | 2016 |
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Drug Monitoring; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Survival Analysis; Treatment Outcome; Tumor Burden; Vincristine | 2017 |
Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Infections; Lymphoma, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Follicular; Middle Aged; Neoplasm Grading; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome | 2018 |
Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Staging; Prednisone; Remission Induction; Retrospective Studies; Rituximab; Survival Analysis; Treatment Outcome; Vincristine | 2018 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dopamine D2 Receptor Antagonists; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Male; Molecular Targeted Therapy; Neoplasm Proteins; Oligopeptides; Piperidines; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Rituximab; Stress, Physiological; Vincristine | 2019 |
Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone.
Topics: Adrenal Cortex Hormones; Bendamustine Hydrochloride; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Prednisone; Retrospective Studies | 2018 |
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Datasets as Topic; Doxorubicin; Female; Humans; Lymphoma, B-Cell; Male; Medicare; Middle Aged; Neoplasms, Second Primary; Prednisone; Progression-Free Survival; Propensity Score; Registries; Rituximab; Treatment Outcome; United States; Vincristine | 2020 |
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Prednisone; Radiotherapy; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Time Factors; Vincristine | 2020 |
Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Immunoglobulins, Intravenous; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Lymphopenia; Magnetic Resonance Imaging; Maintenance Chemotherapy; Middle Aged; Plasmapheresis; Prednisone; Recurrence; Rituximab; Vincristine | 2020 |
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Grading; Prednisone; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2020 |
Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Rituximab; Vincristine | 2020 |
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Blood Platelets; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prednisone; Progression-Free Survival; Proportional Hazards Models; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2021 |
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Predictive Value of Tests; Prednisone; Prognosis; Retrospective Studies; Treatment Outcome | 2021 |
When to consider Pneumocystis jirovecii prophylaxis in HIV-negative patients.
Topics: Aged; Anti-Bacterial Agents; Bendamustine Hydrochloride; HIV Seronegativity; Humans; Immunocompromised Host; Lung Diseases, Interstitial; Lymphoma, Mantle-Cell; Male; Opportunistic Infections; Pneumonia, Pneumocystis; Prednisone; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Rituximab; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Neoplasm Proteins; Prednisone; Prognosis; Risk; Rituximab; RNA, Neoplasm; Transcriptome; Vincristine | 2021 |
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemical and Drug Induced Liver Injury; Cyclophosphamide; Doxorubicin; Female; Health Care Costs; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Prednisone; Renal Insufficiency; Retrospective Studies; Rituximab; Stroke; Vincristine | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Delivery of Health Care; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Medicare; Prednisone; Retrospective Studies; Rituximab; United States; Vincristine | 2021 |
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Prospective Studies; Rituximab; Vincristine | 2022 |
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Rituximab; Sweden; Vincristine | 2022 |
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.
Topics: Bendamustine Hydrochloride; Biomarkers; Cyclophosphamide; Doxorubicin; Enhancer of Zeste Homolog 2 Protein; Humans; Lymphoma, Follicular; Mutation; Neoplasm Recurrence, Local; Prednisone; Retrospective Studies; Rituximab; Vincristine | 2022 |
Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Prednisone; Retrospective Studies; Rituximab; Transplantation, Autologous; Vincristine | 2023 |
Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Ontario; Prednisone; Retrospective Studies; Rituximab; Vincristine | 2023 |